TRPM1 (Melastatin-1/MLSN1) mRNA expression in Spitz nevi and nodular melanomas

Modern Pathology

Volumn 22, Issue 7, 2009, Pages 969-975

  Erickson, Lori A ^a   Letts, Gary A ^a,b   Shah, Sonali M ^a,c   Shackelton, Jeffrey B ^a   Duncan, Lyn M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Melanoma; Melastatin; Prognosis; Spitz nevi; TRPM1

Indexed keywords

MELASTATIN 1; MESSENGER RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHILD; FEMALE; HUMAN; IN SITU HYBRIDIZATION; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MALE; MELANOMA; MIDDLE AGED; NEVUS, EPITHELIOID AND SPINDLE CELL; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS; SURVIVAL RATE; TRPM CATION CHANNELS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67650699964     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.56     Document Type: Article

References (26)

1. Darier J, Civatte A. Naevus ou naevo-carcinoma chez un nourisson. Bull Soc Fr Derm Syph 1910;21:61-63.
2. Pack G, Persik S, Scharfnagel I. Treatment of malignant melanoma: report of 862 cases. Calif Med 1947;66:283-287.
3. Spitz S. Melanomas of childhood. Am J Pathol 1948;24:591-609.
4. Spatz A, Calonje E, Handfield-Jones S, et al. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999;135:282-285.
5. Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 1953;6:1-45.
6. Barnhill RL, Argenyi ZB, From L, et al. Atypical spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30:513-520.
7. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
8. Duncan LM, Deeds J, Hunter J, et al. Downregulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998;58:1515-1520.
9. Deeds J, Cronin F, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 2000;31:1346-1356.
10. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-576.
11. Hammock L, Cohen C, Carlson G, et al. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.. J Cutan Pathol 2006;33:599-607.
12. Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. Nat Rev Neurosci 2001;2:387-396.
13. Hunter JJ, Shao J, Smutko JS, et al. Chromosomal localization and genomic characterization of the mouse melastatin gene (MLSN-1). Genomics 1998;54:116-123.
14. Miller AJ, Du J, Rowan S, et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 2004;64:509-516.
15. Lee K, Lanske B, Karaplis AC, et al. Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 1996;137:5109-5118.
16. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002;20:2530-2536.
17. Madireddi MT, Su ZZ, Young CS, et al. Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. Adv Exp Med Biol 2000;465:239-261.
18. Madireddi MT, Dent P, Fisher PB. Regulation of mda-7 gene expression during human melanoma differentiation. Oncogene 2000;19:1362-1368.
19. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002;168:6041-6046.
20. Ellerhorst JA, Prieto VG, Ekmekcioglu S, et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 2002;20:1069-1074.
21. Bouffard D, Duncan LM, Howard CA, et al. Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol 1994;25:709-714.
22. Bergman R, Azzam H, Sprecher E, et al. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol 2000;42:496-500.
23. Ichikawa T, Masumoto J, Kaneko M, et al. Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol 1998;138:763-768.
24. Lee CS, Pirdas A, Lee MW. Immunohistochemical demonstration of the nm23-H1 gene product in human malignant melanoma and Spitz nevi. Pathol 1996;28:220-224.
25. van den Oord JJ, Maes A, Stas M, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1996;149:1953-1961.
26. Zubovits J, Buzney E, Yu L, et al. HMB-45, S-100, NK1/ C3, and MART-1 in metastatic melanoma. Hum Pathol 2004;35:217-223.